Clinical Trials

Since its inception, SOTIO has sponsored 14 clinical trials across a range of technologies and cancer indications. Currently,  SOTIO Biotech runs Phase 1/1b clinical trial to evaluate the safety and efficacy of SOT101, an IL-15 superagonist.  The company is also finalizing preclinical studies with its proprietary antibody-drug conjugates and CAR T platforms with the aim to initiate first-in-human clinical trials soon. SOTIO and its partners are collaborating to rapidly advance these programs through clinical development stage and towards commercialization.